A reversal of type 2 diabetes (T2D) may be possible with low-calorie liquid diet for up to 5 months, increased physical activity, and cognitive behavioural therapy, preliminary results of the DiRECT* trial has shown.
A titratable, fixed-ratio combination of insulin glargine 100 U/mL and the GLP-1* receptor agonist lixisenatide was associated with favourable glycaemic and gastrointestinal outcomes in patients with type 2 diabetes (T2D), according to several studies presented at IDF 2017.
The cardiovascular (CV) efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes (T2D) appear to be a class effect, according to a systematic review and meta-analysis of four major GLP-1 CV safety trials.
Adding liraglutide treatment to standard of care (SoC) reduced the risk of worsening glycaemic control, along with greater reductions in HbA1c levels in patients with type 2 diabetes (T2D) compared with SoC alone, according to long-term data of the LEADER trial presented at IDF 2017. Risk of amputation also appeared to be lower in liraglutide-treated patients with diabetic foot ulcer (DFU).
Long-term treatment with testosterone undecanoate (TU) in hypogonadal men with type 2 diabetes (T2D) resulted in substantial and sustained weight loss compared with untreated individuals, according to registry studies presented at the IDF 2017.
Use of metformin during the first trimester of pregnancy showed no significant maternal or foetal adverse outcomes in women with gestational diabetes mellitus (GDM), according to a study presented at IDF 2017.
Individuals with type 2 diabetes (T2D) who underwent bariatric surgery experienced significant reductions in several cardiometabolic risk factors up to 5 years post-surgery, according to a study from the UK. However, as the number of patients who achieved T2D remission was low, surgery alone may not be sufficient to manage metabolic risk factors.
The protective effects of liraglutide against the risks of cardiovascular (CV) events and deaths may be reduced in patients with type 2 diabetes (T2D) who experienced severe hypoglycaemia, but were independent of patient’s history of CV events at baseline, according to post hoc analyses of the LEADER* trial.
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
New drug applications approved by US FDA as of 16 - 31 May 2017 which
includes New Molecular Entities (NMEs) and new biologics. It does not
include Tentative Approvals. Supplemental approvals may have occurred
since the original approval date.